MA53138B1 - 3-(5-HYDROXY-1-OXOISOINDOLINE-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2) DEPENDENT DISEASES - Google Patents
3-(5-HYDROXY-1-OXOISOINDOLINE-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2) DEPENDENT DISEASESInfo
- Publication number
- MA53138B1 MA53138B1 MA53138A MA53138A MA53138B1 MA 53138 B1 MA53138 B1 MA 53138B1 MA 53138 A MA53138 A MA 53138A MA 53138 A MA53138 A MA 53138A MA 53138 B1 MA53138 B1 MA 53138B1
- Authority
- MA
- Morocco
- Prior art keywords
- ikzf2
- treatment
- zinc finger
- oxoisoindoline
- piperidine
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 title 2
- 102100037796 Zinc finger protein Helios Human genes 0.000 title 2
- JJUMFQGCQAUIFH-UHFFFAOYSA-N 3-(6-hydroxy-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC(O)=CC=C2C(=O)N1C1CCC(=O)NC1=O JJUMFQGCQAUIFH-UHFFFAOYSA-N 0.000 title 1
- 102000039995 Ikaros C2H2-type zinc-finger protein family Human genes 0.000 abstract 1
- 108091069197 Ikaros C2H2-type zinc-finger protein family Proteins 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (i') : ou un sel, un hydrate, un solvate, un promédicament, un stéréoisomère ou un tautomère pharmaceutiquement acceptable de celui-ci, dans laquelle rx, x1, x2, et r1 sont tels que définis dans la description, et son utilisation dans le traitement de maladies dépendantes du doigt de zinc 2 de la famille ikaros (ikzf2).The present invention relates to a compound of formula (i'): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof, wherein rx, x1, x2, and r1 are such as defined in the description, and its use in the treatment of diseases dependent on zinc finger 2 of the ikaros family (ikzf2).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862695920P | 2018-07-10 | 2018-07-10 | |
PCT/IB2019/055804 WO2020012334A1 (en) | 2018-07-10 | 2019-07-08 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
MA53138A MA53138A (en) | 2021-05-19 |
MA53138B1 true MA53138B1 (en) | 2023-10-31 |
Family
ID=75905122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA53138A MA53138B1 (en) | 2018-07-10 | 2019-07-08 | 3-(5-HYDROXY-1-OXOISOINDOLINE-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2) DEPENDENT DISEASES |
Country Status (2)
Country | Link |
---|---|
AR (1) | AR116110A1 (en) |
MA (1) | MA53138B1 (en) |
-
2019
- 2019-07-05 AR ARP190101914A patent/AR116110A1/en unknown
- 2019-07-08 MA MA53138A patent/MA53138B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA53138A (en) | 2021-05-19 |
AR116110A1 (en) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49952B1 (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
PH12021550045A1 (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
MA47368B1 (en) | N- [4-fluoro-5 - [[(2s, 4s) -2-methyl-4 - [(5-methyl-1,2,4-oxadiazol-3-yl) methoxy] -1-piperidyl] methyl] thiazol-2-yl] acetamide used as an inhibitor of yoga | |
MX2020001776A (en) | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP<sub>3</sub> INHIBITORS. | |
CR20200588A (en) | Novel compounds | |
GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
MA30433B1 (en) | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES FOR TREATING RESPIRATORY DISORDERS | |
MA46337B1 (en) | Pyridine compound | |
MA42339A1 (en) | Farnesoid Receptor Modulators x | |
MA43169B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
MA45888A1 (en) | Bruton tyrosine kinase inhibitors | |
MA45020B1 (en) | Aromatic sulfonamide derivatives | |
MA46101A (en) | POSITIVE ALLOSTERIC MODULATORS OF THE M1 MUSCARINIC RECEPTOR | |
EA202192900A1 (en) | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAYS | |
MA51431B1 (en) | Oxy-fluoropiperidine derivatives used as kinase inhibitor | |
PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
MA41494A (en) | BENZOXABOROLE COMPOUNDS SUBSTITUTED IN POSITION 4 AND ASSOCIATED USES | |
EA201992090A1 (en) | Deuterated Imidazo [4,5-c] Quinolin-2-One Compounds and Their Use in Cancer Treatment | |
MX2021008632A (en) | Cyclic molecules as bruton's tyrosine kinase inhibitor. | |
EA202092253A1 (en) | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | |
MA50069B1 (en) | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND SIMILAR COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR THE TREATMENT OF DISEASES AUTOIMMUNE AND CHRONIC INFLAMMATION | |
MX2020008523A (en) | Compound having s1p5 receptor agonist activity. | |
MX2022004912A (en) | Novel substituted condensed ring compound. | |
MA53138B1 (en) | 3-(5-HYDROXY-1-OXOISOINDOLINE-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2) DEPENDENT DISEASES | |
EA202191349A1 (en) | 1,3,4-OXADIAZOLONE AND PHARMACEUTICAL PREPARATION |